UBS Group reiterated their neutral rating on shares of Novartis (NYSE:NVS) in a research report report published on Monday morning, www.boersen-zeitung.de reports.

Several other research firms have also weighed in on NVS. JPMorgan Chase & Co. restated a neutral rating on shares of Novartis in a report on Tuesday, September 26th. Zacks Investment Research lowered shares of Novartis from a buy rating to a hold rating in a report on Thursday, September 21st. Leerink Swann lifted their target price on shares of Novartis from $89.00 to $91.00 and gave the company a market perform rating in a report on Monday, October 23rd. Nord/LB restated a neutral rating on shares of Novartis in a report on Tuesday, January 2nd. Finally, Bank of America lowered shares of Novartis from a neutral rating to an underperform rating in a report on Wednesday, December 6th. Five analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus price target of $85.32.

Novartis (NVS) traded down $0.47 during trading hours on Monday, hitting $86.41. 1,523,700 shares of the company traded hands, compared to its average volume of 1,071,025. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.08 and a quick ratio of 0.81. The firm has a market cap of $225,650.00, a price-to-earnings ratio of 30.75, a price-to-earnings-growth ratio of 2.32 and a beta of 0.74. Novartis has a 1-year low of $69.53 and a 1-year high of $87.29.

Novartis (NYSE:NVS) last posted its earnings results on Tuesday, October 24th. The company reported $1.29 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.25 by $0.04. The business had revenue of $12.41 billion for the quarter, compared to analyst estimates of $12.21 billion. Novartis had a net margin of 13.73% and a return on equity of 15.77%. The business’s quarterly revenue was up 2.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.23 EPS. equities research analysts forecast that Novartis will post 4.79 EPS for the current year.

A number of hedge funds have recently modified their holdings of the business. WFG Advisors LP increased its position in shares of Novartis by 38.1% in the 2nd quarter. WFG Advisors LP now owns 1,221 shares of the company’s stock worth $102,000 after purchasing an additional 337 shares during the last quarter. Wealthcare Advisory Partners LLC bought a new stake in shares of Novartis in the 3rd quarter worth about $106,000. Cable Hill Partners LLC increased its position in shares of Novartis by 588.8% in the 3rd quarter. Cable Hill Partners LLC now owns 1,295 shares of the company’s stock worth $112,000 after purchasing an additional 1,107 shares during the last quarter. Harding Loevner LP bought a new stake in shares of Novartis in the 2nd quarter worth about $146,000. Finally, Sawyer & Company Inc bought a new stake in shares of Novartis in the 4th quarter worth about $183,000. Hedge funds and other institutional investors own 10.85% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Novartis (NVS) Stock Rating Reaffirmed by UBS Group” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2018/01/19/novartis-nvs-stock-rating-reaffirmed-by-ubs-group.html.

Novartis Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.